Impact of off‐label use regulations on patient care in dermatology – a prospective study of cost‐coverage applications filed by tertiary dermatology clinics throughout Germany
Ricardo Niklas Werner(Charité - Universitätsmedizin Berlin), Alexander Nast(Humboldt-Universität zu Berlin), Katharina Amschler(Universitätsmedizin Göttingen), Alexander Zink(Technical University of Munich), Lisa Eisert(Vivantes Klinikum), Antonia Pennitz(Humboldt-Universität zu Berlin), J. Plange(RWTH Aachen University), Paul Schmidle(Technical University of Munich), Ingmar Wolff(Universitätsmedizin Greifswald), Knut Schäkel(Heidelberg University), Sebastian Zielbauer(Goethe University Frankfurt), Susanne Abraham(University Hospital Carl Gustav Carus), Volkmar Müller(Universität Hamburg), Lukas Sollfrank(Universitätsklinikum Erlangen), P. Koll(University of Cologne), M. Goebeler(Universitätsklinikum Würzburg)
Cited by 3
Related Papers
Psoriasis Pathogenesis and Treatment
|International Journal of Molecular Sciences|2019|2k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k